Provided by Tiger Trade Technology Pte. Ltd.

Bristol-Myers Squibb

56.82
-0.7600-1.32%
Volume:4.10M
Turnover:232.06M
Market Cap:115.67B
PE:12.51
High:58.02
Open:57.71
Low:56.15
Close:57.58
52wk High:68.64
52wk Low:42.52
Shares:2.04B
Float Shares:2.03B
Volume Ratio:0.87
T/O Rate:0.20%
Dividend:2.51
Dividend Rate:4.42%
EPS(TTM):4.54
EPS(LYR):3.46
ROE:46.60%
ROA:10.72%
PB:5.18
PE(LYR):16.42

Loading ...

Bristol Phase 3 success with admilparant should send Contineum up, says Stifel

TIPRANKS
·
Yesterday

Bristol-Myers Squibb: Zenbexus Phase III Validates Benefit but Competitive Pressures Keep Risk/Reward Balanced at Hold

TIPRANKS
·
Yesterday

Contineum Tumbles as Bristol's Partial Trial Win Raises Dose Doubts

Reuters
·
Yesterday

US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences

Reuters
·
Yesterday

2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private

InvestorPlace
·
Yesterday

Bristol-Myers Squibb (BMY.US) Climbs in Pre-Market Trading! Two Experimental Drugs Deliver Positive Phase 3 Results, Accelerating Pipeline Diversification

Stock News
·
Yesterday

Bristol Myers' Stock Jumps Nearly 4% as Its Experimental Therapies Show Positive Results in Lung Disease and Cancer Trials

Trading Random
·
Yesterday

Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets Primary Endpoint

MT Newswires Live
·
Yesterday

Bristol Myers Cancer Therapy Meets Main Goal in Late-Stage Study

Reuters
·
Yesterday

Bristol Myers reports ‘positive’ interim analysis of ACTION-1 trial by RayzeBio

TIPRANKS
·
Yesterday

Movement Alert|Bristol-Myers Squibb Rises 4.25% in Pre-Market Trading, Admilparant Phase 3 Pulmonary Fibrosis Trial Meets Primary Endpoint

Market Focus
·
Yesterday

Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 Action-1 for Ryz101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with Gep-Nets

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb Company - Phase 3 Action-1 Study Meets Primary Endpoint with Improved Progression-Free Survival

THOMSON REUTERS
·
Yesterday

Bristol Myers' Lung Disease Drug Meets Main Goal in Late-Stage Trial

Reuters
·
Yesterday

Bristol Myers Squibb Says Phase 3 ALOFT-IPF Trial Shows Admilparant 60 Mg Meets Primary Endpoint

Reuters
·
Yesterday

Bristol-Myers Squibb Company - Admilparant Demonstrates Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb Company - Admilparant Phase 3 Aloft-Ppf Trial Topline Results Expected Early 2027

THOMSON REUTERS
·
Yesterday

Bristol-Myers Squibb Company - Admilparant 120 Mg Dose Slowed Fvc Decline but not Statistically Significant

THOMSON REUTERS
·
Yesterday

Bristol Myers Squibb Announces Phase 3 Aloft-Ipf Trial Evaluating Admilparant in Adults with Idiopathic Pulmonary Fibrosis Met Primary Endpoint

THOMSON REUTERS
·
Yesterday

The $3.8 Billion AI Startup With Zero Drugs — Why Big Pharma Keeps Signing the Checks

AI Industry Frontlines
·
Oct 11